A phase I dose-escalation sequential-cohort of the safety tolerability and pharmacokinetics of intravenous AVE005 [aflibercept] (VEGF Trap) administered every 2 weeks in combination with weekly intravenous gemcitabine then with biweekly intravenous gemcitabine plus oxaliplatin in subjects with advanced solid malignancies
Phase of Trial: Phase I
Latest Information Update: 11 Jun 2008
At a glance
- Drugs Aflibercept (Primary) ; Gemcitabine; Oxaliplatin
- Indications Solid tumours
- Focus Adverse reactions
- 11 Jun 2008 Interim results were presented at the 44th American Society of Clinical Oncology (ASCO) annual meeting.
- 07 Aug 2006 New trial record.